HDT

Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Retrieved on: 
Monday, October 17, 2022
Research, Hospitals, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Effectiveness, Population, Royal commission, SOC, HDT, Patient, Standard of care, Research, CAR, Axicabtagene ciloleucel, B-cell lymphoma, Oncology, Cancer research, Institute of Cancer Research, DLBCL, CEO, EFS, Adult, Non-Hodgkin lymphoma, Chimeric antigen receptor T cell, EC, ASCT, European Commission, Pharmaceutical industry

Yescarta is now the first Chimeric Antigen Receptor (CAR) T-cell therapy approved for patients in Europe who do not respond to first-line treatment.

Key Points: 
  • Yescarta is now the first Chimeric Antigen Receptor (CAR) T-cell therapy approved for patients in Europe who do not respond to first-line treatment.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common sub-type of non-Hodgkin lymphoma (NHL), representing around 30% of cases.
  • Yescarta was first approved in Europe in 2018 and is currently indicated for five types of blood cancer: Diffuse Large B-Cell Lymphoma (DLBCL); Large B-Cell Lymphoma (LBCL); High-Grade B-Cell Lymphoma (HGBL); Primary Mediastinal Large B-Cell Lymphoma (PMBCL); and Follicular Lymphoma (FL).
  • Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

A. Duie Pyle's Greg Mellon Honored as an HDT 2022 Top Emerging Leader

Retrieved on: 
Monday, October 10, 2022
Time, Mellon, Government, Transport, VP, HDT, Knowledge, Software, LTL, Industry, Pyle, GLOBE, Maintenance, Running, Solution, Management, Dedicated

The award recognizes young trucking industry leaders working at fleet companies who are already making a difference in their fields.

Key Points: 
  • The award recognizes young trucking industry leaders working at fleet companies who are already making a difference in their fields.
  • He also led the implementation of the fleets maintenance software, AssetWorks FleetFocus, and headed training efforts.
  • Throughout his time in management, Mellon has hired and developed a team of people to help accomplish the fleets expectations.
  • Im honored to be recognized by HDT as a Top Emerging Leader, and Im excited to keep growing with my team at Pyle.

HDT Global Announces the Acquisition of Federal-Fabric-Fibers, Inc.

Retrieved on: 
Tuesday, October 4, 2022
Solution, 3F, HDT, Government, Tent, SVP, Robotics, Technology, CEO, Multimedia, Acquisition, 3D printing

In operation for 85 years, HDT is the world leader in the design and production of expeditionary solutions for austere locations.

Key Points: 
  • In operation for 85 years, HDT is the world leader in the design and production of expeditionary solutions for austere locations.
  • Known for our state-of-the art, rapidly deployable rigid wall and soft wall shelter systems, HDT's mobile infrastructure solutions are used by the US armed forces and allied foreign military.
  • With this completed transaction, HDT adds Federal-Fabrics-Fibers' line of 2- and 3-D shaped woven technology (AirBeam) shelter systems to its already impressive line-up of folding frame and air-supported soft wall shelters.
  • "HDT is pleased to welcome the Fed-Fab employees to our team," stated Juan A. Navarro, HDT Global President and CEO.

Ashvattha Therapeutics Announces Preclinical Data on Hydroxyl Dendrimer Based PET Tracer [18F]OP-801 Presented at the 2022 World Molecular Imaging Congress

Retrieved on: 
Thursday, September 29, 2022
Neuro, Plasma, Therapy, Inflammation, Multiple sclerosis, Spinal cord, Lists of diseases, Nanomedicine, QC, Microglia, Biomarker, HDS, Miami Beach Convention Center, Neurodegeneration, Quality control, Diabetic retinopathy, Macrophage, DME, HDT, Mouse, MS, Patient, PET, EAE, CEO, Ashvattha, Doctor of Philosophy, Johns Hopkins University, Traffic barrier, Autoradiograph, Neurology, Stanford University, ALS, AMD, GLOBE, HD, Neuroinflammation, Dosimetry, Disease, Radiology, Pharmaceutical industry, Medical imaging, Marketing, Trapping, Ophthalmology, CSF1R

REDWOOD CITY, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics, today announced preclinical data presented by collaborators from Stanford University demonstrating that its hydroxyl dendrimer (HD)-based PET tracer, [18F]OP-801, can detect activated macrophages and microglia with high sensitivity and specificity in an experimental autoimmune encephalomyelitis (EAE) murine model of multiple sclerosis (MS), in addition to being reproducibly synthesized and suitable for human use. The data were presented at the World Molecular Imaging Congress being held September 28th – October 1st, 2022, at the Miami Beach Convention Center in Miami, FL.

Key Points: 
  • The data were presented at the World Molecular Imaging Congress being held September 28th October 1st, 2022, at the Miami Beach Convention Center in Miami, FL.
  • PET imaging data was corroborated by autoradiography images, showing significantly higher signal in the lumbar spinal cord of untreated compared to treated EAE mice.
  • Human dosimetry estimates based on mouse imaging data are conducive to translation and clinical imaging of [18F]OP-801.
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology.

Northrop Grumman Meets Rocket Motor Casting Milestone on Road to Sentinel’s First Flight

Retrieved on: 
Wednesday, September 21, 2022
Sentinel, General Dynamics, Engineering, NYSE, CAE, Risk, Northrop, Northrop Grumman, The, Program, Grumman, HDT, Kratos Defense & Security Solutions, Wind, Vandenberg Space Force Base, Air force, Textron, Â, Honeywell, GLOBE, Leg, NOC, United, 3D printing

PROMONTORY, Utah, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Northrop Grumman Corporation (NYSE: NOC) successfully cast the LGM-35A Sentinel programs first inert stage-one and stage-two solid rocket motor set this summer.

Key Points: 
  • PROMONTORY, Utah, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Northrop Grumman Corporation (NYSE: NOC) successfully cast the LGM-35A Sentinel programs first inert stage-one and stage-two solid rocket motor set this summer.
  • The casting event demonstrated the maturity of Sentinels solid rocket motor design and validated manufacturing processes, advanced tooling, and facilities.
  • Motor casting is a complex process of pouring rocket motor propellant into motor cases.This completed motor set is undergoing further processing and inspection before participating in modal testing.
  • In June, Northrop Grumman produced the first stage-one and stage-two nozzle builds and igniter assemblies to install on these motors during rocket motor assembly later this year.

Ashvattha Therapeutics Announces Presentations of Preclinical Data on Hydroxyl Dendrimer-Based PET Tracer [18F]OP-801 at the 2022 World Molecular Imaging Congress (WMIC)

Retrieved on: 
Thursday, September 15, 2022
Neuro, Therapy, Inflammation, Multiple sclerosis, Human, Nanomedicine, Microglia, HDS, Miami Beach Convention Center, Neurodegeneration, CSF1, Diabetic retinopathy, DME, HDT, Patient, PET, WMIC, Google Images, Ashvattha, Johns Hopkins University, Traffic barrier, Amyotrophic lateral sclerosis, Neurology, Stanford University, ALS, AMD, GLOBE, HD, Congress, Medical imaging, Ophthalmology

REDWOOD CITY, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics, today announced presentations of preclinical data on the selective uptake of its hydroxyl dendrimer-based PET tracer, [18F]OP-801, in the spines of a murine model of multiple sclerosis and a reduction in the PET signal after treatment with a hydroxyl dendrimer therapeutic (HDT) that inhibits CSF1 receptors. In addition, data on the synthesis of [18F]OP-801 suggests a reliable and high yielding method suitable for diagnostic imaging in humans. The data will be presented by scientific collaborators from Stanford University at the 2022 World Molecular Imaging Congress (WMIC), taking place at the Miami Beach Convention Center in Miami, FL, September 28 – October 1, 2022.

Key Points: 
  • In addition, data on the synthesis of [18F]OP-801 suggests a reliable and high yielding method suitable for diagnostic imaging in humans.
  • The data will be presented by scientific collaborators from Stanford University at the 2022 World Molecular Imaging Congress (WMIC), taking place at the Miami Beach Convention Center in Miami, FL, September 28 October 1, 2022.
  • Presentation details can be found below:
    [18F]OP-801 is a hydroxyl dendrimer (HD) imaging agent that provides information on uptake of HDs across tissue barriers including the blood-brain barrier.
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology.

Ashvattha Therapeutics Announces First Patient Enrolled in a Phase 2 Study of D-4517.2 for the Treatment of Wet AMD and DME 

Retrieved on: 
Wednesday, September 7, 2022
Inflammation, Johns Hopkins University, IVT, Research, Covalent bond, Human, Blood, Safety, HDT, CEO, Ashvattha, Liver, Therapy, Macrophage, Toxicity, Disease, Traffic barrier, World, Severe cognitive impairment, Microglia, Pathology, ARVO, Diabetic retinopathy, VEGF, Injection, DME, VEGFR, Cell, Neurology, Animal, Nanomedicine, MD, GLOBE, Patient, Neuro, AMD, HDS, Eye, Growth, World Health Organization, Pharmaceutical industry, Vaccine, Ophthalmology, Retina

REDWOOD CITY, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics (HDT), today announced that the first patient has been enrolled in a two-stage Phase 2 clinical study of D-4517.2, an HDT with potent anti-VEGF activity. This study aims to evaluate the safety and efficacy of a subcutaneous (SC) injection of D-4517.2 at different dose levels in comparison to intravitreal (IVT) injection of aflibercept, an approved therapy, in patients suffering from wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME). 

Key Points: 
  • We are excited to initiate the first stage of our Phase 2 study evaluating our subcutaneous anti-VEGF wet AMD and DME candidate, D-4517.2.
  • A subcutaneously administered treatment offers an at-home option that patients can administer themselves, said Jeffrey Cleland, Ph.D., Chairman, CEO and President of Ashvattha Therapeutics.
  • Best-corrected visual acuity (BCVA) in the study eye will also be measured for each patient during the 12-week treatment period.
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology.

HDT Automotive Names New CFO James Habel

Retrieved on: 
Wednesday, August 31, 2022
Foam, Bachelor of Business Administration, University, University of Michigan–Dearborn, Business administration, CTP, HDT, Solution, TRW, Board, Visteon, Certified Treasury Professional, IFRS, CFO, Treasury, Retirement, Leadership, Patrick, International, ZF, PKC Group, Ford Motor Company, EPP, Institute of Public Accountants, Director, EPS, Industry, Ross School of Business, CPA, International Financial Reporting Standards, Anselmi, Management, Habel

John Anselmi will retire Sept. 1 and transition to advisory role and Board Member

Key Points: 
  • John Anselmi will retire Sept. 1 and transition to advisory role and Board Member
    LIVONIA, Mich., Aug. 31, 2022 /PRNewswire/ -- HDT Automotive Solutions (HDT Automotive), a leading global supplier of fluid-handling systems and precision aluminum parts, today announced the appointment of James Habel as its Chief Financial Officer.
  • Habel replaces John Anselmi, who, after serving as HDT's CFO for more than four years, will retire effective September 1st.
  • After a smooth transition of responsibilities to Habel, Anselmi will continue to work with HDT Automotive in an advisory role and Vice Chairman.
  • HDT Automotive Solutions is a leading global supplier of automotive tubular components, with a diverse array of products, new materials capabilities, a worldwide manufacturing footprint, and a well-balanced customer base.

HDT Global Announces the Appointment of James Cassella as Chief Revenue Officer

Retrieved on: 
Tuesday, August 30, 2022
VP, DI, CEO, Pentagon, Aviation, HDT, Army, Engineering, DynCorp, Solution, General Staff of the Army of Republika Srpska, Robotics, Department of Defence, Business development, Defense Clandestine Service, SVP, Senior, Leadership, Proposed developments of Manchester Metrolink, Leonardo DRS, Acquisition, Growth, Army aviation, Management, Amentum, Defense

SOLON, Ohio, Aug. 30, 2022 /PRNewswire/ -- HDT Global (HDT), a leading manufacturer and integrator of highly-engineered unmanned, robotics, platform, and expeditionary solutions across defense, aerospace and government markets, announced today the appointment of James Cassella as Senior Vice President and Chief Revenue Officer.

Key Points: 
  • SOLON, Ohio, Aug. 30, 2022 /PRNewswire/ -- HDT Global (HDT), a leading manufacturer and integrator of highly-engineered unmanned, robotics, platform, and expeditionary solutions across defense, aerospace and government markets, announced today the appointment of James Cassella as Senior Vice President and Chief Revenue Officer.
  • Mr. Cassella brings more than 25 years of experience in business development and corporate growth strategy to his new role at HDT.
  • Prior to joining HDT, Mr. Cassella served as Chief Growth Officer for DynCorp International (DI), responsible for business development, mergers and acquisitions, and corporate strategy.
  • "I'm especially excited to be joining HDT Global at a time when the company is poised for significant growth," said Mr. Cassella.

Ashvattha Therapeutics Announces Preclinical Data at the 2022 Alzheimer’s Association International Conference (AAIC) Demonstrating its Hydroxyl Dendrimer-Based Imaging Agent [18F]OP-801 Can Detect Early-Stage Neuroinflammation with a Higher Sensitivity

Retrieved on: 
Monday, August 1, 2022
CA, AAIC, Traffic barrier, Brain, Spinal cord, Stanford University, Inflammation, Lists of diseases, GLOBE, Ashvattha, TSPO, DME, Physician, Amyotrophic lateral sclerosis, Microglia, Neurodegeneration, CEO, AMD, Neuroinflammation, PET, Therapy, Conference, Neuro, KDA, HDS, ALS, Disease, Technology, Patient, HDT, San Diego Convention Center, Neurology, Diabetic retinopathy, Mouse, Johns Hopkins University, Macrophage, HD, Medical imaging, Ophthalmology

The data also build on previous studies and validates our hydroxyl dendrimers ability to cross the blood-brain barrier and be selectively taken up by reactive inflammatory cells.

Key Points: 
  • The data also build on previous studies and validates our hydroxyl dendrimers ability to cross the blood-brain barrier and be selectively taken up by reactive inflammatory cells.
  • By measuring the extent of [18F]OP-801 uptake in the brain, we will be able select patients with HD uptake based on PET signal.
  • These patients will then be treated with the same HD chemically linked to a drug to treat the disease.
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammatory diseases and neuro-oncology.